Oral metronomic therapy in head and neck cancer
-
Published:2021-01
Issue:1
Volume:9
Page:e20
-
ISSN:2214-109X
-
Container-title:The Lancet Global Health
-
language:en
-
Short-container-title:The Lancet Global Health
Author:
Sharma Vinod,Kumar Akash
Reference4 articles.
1. Low-cost oral metronomic chemotherapy versus intravenous cisplatin in patients with recurrent, metastatic, inoperable head and neck carcinoma: an open-label, parallel-group, non-inferiority, randomised, phase 3 trial;Patil;Lancet Glob Health,2020
2. Re-challenge of platinum-based chemotherapy for platinum-refractory patients with recurrent or metastatic head and neck cancer: claims data analysis in Japan;Tahara;J Health Econ Outcomes Res,2020
3. Weekly paclitaxel for platin-resistant stage IV head and neck cancer patients;Grau;Acta Otolaryngol,2008
4. Weekly docetaxel in patients with platinum-refractory metastatic or recurrent squamous cell carcinoma of the head and neck;Cho;Cancer Chemother Pharmacol,2009